GlassScriptPhysician profile
Bradley G Marple
NPI 1760914691
$1,142.22
in general payments reported to CMS, 2019-2025
13 companies · $96.62 in 2025
The $96.62 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $30.04 · 2021: $206 · 2022: $235 · 2023: $394 · 2024: $180 · 2025: $96.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $318.07 | 2020-2025 | Bexsero, Pediarix, Rotarix |
| Ironshore Pharmaceuticals INC. | $216.50 | 2022-2024 | Jornay Pm |
| Corium, LLC | $200.91 | 2022-2024 | Azstarys |
| Rhythm Pharmaceuticals, INC. | $125.00 | 2023 | Imcivree |
| Takeda Pharmaceuticals U.S.A., INC. | $83.09 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $36.87 | 2025 | Jornay Pm |
| Pfizer INC. | $36.75 | 2021 | |
| Supernus Pharmaceuticals, INC. | $26.57 | 2021 | |
| Sanofi Pasteur INC. | $26.42 | 2023 | |
| Ptc Therapeutics, INC. | $20.92 | 2022 | |
| Biowound Solutions, INC. | $20.33 | 2025 | Bio-Connekt |
| Biomarin Pharmaceutical INC. | $17.53 | 2024 | Voxzogo 1.2mg |
| Exeltis, USA INC. | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Marple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.